Ulcerative colitis (UC) is a chronic, debilitating disease that affects the large intestine or colon. The cause of ulcerative colitis is unknown, but researchers believe it is an exaggerated immune response to the triggering of microorganisms. UC is characterized by inflammation in the colon, the symptoms of which include blood in the stool, diarrhea and abdominal pain.
According to Pfizer, UC affects about one million people every year in the United States. Treatment of UC involves traditional therapies such as tumor necrosis factor (TNF) inhibitors and drugs consisting of small molecules. The global ulcerative colitis market is expected to account for $ 4,785 million in 2016, reaching $ 7,455 million by 2023, with a 6.5% CAGR from 2017 to 2023.
Ulcerative colitis is an inflammatory bowel disease that affects the colon and rectum of the human body. The disease affects people of any age and most commonly it begins during adolescence and early adulthood, but it may also occur later in life. Ulcerative colitis is highly prevalent in the U.S., England, and northern Europe. The most commonly preferred treatment options for ulcerative colitis are traditional medications made of biologics and small molecules.
The prime factors factor that drive global ulcerative colitis market are increase in prevalence of ulcerative colitis globally and rise in R&D activities by key players towards new drug formulations for disease treatment. In addition, increase in patient assistance programs that has raised the demand for branded drugs further fuels the market growth. Untapped emerging economies that lack proper medical assistance are expected to provide numerous opportunities for market expansion.
The oral segment dominated the ulcerative colitis market with half of the market share in 2016, as it is an easy route of administration and immediate destruction of drugs by gastric acid is avoided. The injectable segment is expected to register the highest CAGR of 6.9%.
The moderate disease type segment is expected to witness highest growth rate throughout the forecast period, with a CAGR of 6.8%. This is due the exponential increase in prevalence of ulcerative colitis and lack of awareness in emerging economies coupled with unavailability of proper treatment modalities and drug approvals. This leads to conversion of an ulcerative colitis disease from mild state to moderate state.